TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Inimmune and Boston Children's Hospital Join Forces to Pave the Way for Innovative Adjuvant Development

Wednesday, October 25, 2023

Inimmune Corporation, a clinical-stage biotechnology company focused on developing innovative immunotherapeutics, has announced a research collaboration with Boston Children's Hospital (BCH) to create novel small molecule vaccine adjuvants. These adjuvants are substances added to certain vaccines to enhance the immune response, resulting in stronger and longer-lasting immunity against infections when used in combination with the vaccines.

The Precision Vaccines Program (PVP) at Boston Children's Hospital was awarded a contract (Contract No: 75N93023C00040) by the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID). This contract can extend up to five years and provides up to $9 million in funding to develop a small molecule TLR7/8 agonist adjuvant designed to improve the effectiveness of flu vaccines.

The PVP, located in the Department of Pediatrics at Boston Children's Hospital, is a research program dedicated to discovering and developing the next generation of vaccines tailored to protect vulnerable populations.

The Precision Vaccines Program is committed to pioneering the next generation of vaccines designed to protect the most vulnerable individuals. We are establishing a global network to revolutionize vaccine development, and we are enthusiastic about partnering with Inimmune to improve adjuvants.

PVP faculty member and joint principal investigator, explained, "Starting with protein-based flu vaccines, we are laying the foundation for an approach that has the potential to enhance not only this platform but also other technologies, including mRNA vaccines, in the battle against infectious diseases."

Inimmune is actively involved in researching new classes of adjuvants and immunotherapies for vaccines and other medical indications, with several programs making significant progress. In the recent past, Inimmune successfully moved a candidate immunotherapy for the treatment of allergic rhinitis into Phase I clinical trials.

Under this collaboration, Inimmune will work closely with Boston Children's investigators to advance the development of new adjuvants, including their synthesis, formulation, and pre-clinical evaluation. Once preclinical proof-of-concept is achieved, they will seek commercial collaborations to further develop these innovations.

Inimmune, stated, "At Inimmune, we are committed to identifying and developing unique immunotherapeutics. By leveraging Inimmune's drug discovery expertise and resources, PVP researchers can fully realize the therapeutic potential of their novel adjuvants.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit